PDF-Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments on the draft guidance to http. 574115745557453574535744557454574605745957376574415745457444573765745957461574475744757445574595746057449574555745457459573765745857445574475744157458574445744957454574475737657460574485744957459573765744457458574415744657460573765744457455574435746 Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit written comments to the Di vision of Dockets Mana 5741157455574535745357445574545746057459573765744157454574445737657459574615744757447574455745957460574495745557454574595737657458574455744757441574585744457449574545744757376574605744857449574595737657444574585744157446574605737657444 Comments and suggestions regarding this draft document should be subm itted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Management H Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Management HF Com ents and suggestio ns regar ing this draft do cu ent should be sub itted wit in 9 0 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Subm it comments to the D ivision of Dockets Manage e Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Sub Comments and suggestions regarding this draft docu ment should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Management H G:\4156dft.doc 09/30/03 G:\4156dft.doc http://www.fda.gov/cvm/guidance/guidance.htmlhttp://www.cfsan.fda.gov/~dms/guidance.html 09/30/03 G:\4156dft.doc WHAT FILE FORMATS SHOULD I USPage S Office of Research Protections, Policy, & Education. VHA Office of Research and Development. Department of Veterans Affairs . March 18, 2020. Dial in: 1 (213)-929-4232. Access Code: 152-743-880. G:\5412dft.doc01/02/03 G:\5412dft.doc01/02/03 The Division of Drug Information (HFD-240)Center for Drug Evaluation and Research (Tel) 301-827-4573 Draft — Not for ImplementationG:\5412dft.doc01/0 For VA Personnel Conducting Expanded Access Program Activities for the Treatment of Patients with Monkeypox. (May be Used in Lieu of CITI Modules for ORD-Required Training in Human Subjects Ethical Protections). Dr. Sonalika’s Eye Clinic provide the best Eye infection treatment, Conjunctivitis treatment in pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri Dr. Sonalika’s Eye Clinic provide the best Conjunctivitis (Pink Eye) treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri